Merck KGaA banner

Merck KGaA
OTC:MKGAF

Watchlist Manager
Merck KGaA Logo
Merck KGaA
OTC:MKGAF
Watchlist
Price: 132.81 USD 3.66% Market Closed
Market Cap: $57.7B

P/FCFE

13.1
Current
68%
Cheaper
vs 3-y average of 41.1

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
13.1
=
Market Cap
$47B
/
Free Cash Flow to Equity
€3.7B

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
13.1
=
Market Cap
$47B
/
Free Cash Flow to Equity
€3.7B

Valuation Scenarios

Merck KGaA is trading below its 3-year average

If P/FCFE returns to its 3-Year Average (41.1), the stock would be worth $415.28 (213% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+283%
Average Upside
158%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 13.1 $132.81
0%
3-Year Average 41.1 $415.28
+213%
5-Year Average 50.3 $508.47
+283%
Industry Average 22 $222.19
+67%
Country Average 22 $222.19
+67%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
DE
Merck KGaA
OTC:MKGAF
47.8B USD 13.1 18.4
US
Eli Lilly and Co
NYSE:LLY
908.9B USD 61.3 36
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 21 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 27.5 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 36.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 9.4 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 12.2 31.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD -766.6 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 24.3 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 24.3 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.9B USD 37.8 4 516.9
P/E Multiple
Earnings Growth PEG
DE
Merck KGaA
OTC:MKGAF
Average P/E: 472.8
18.4
17%
1.1
US
Eli Lilly and Co
NYSE:LLY
36
32%
1.1
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
31.1
14%
2.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
4 516.9
648%
7

Market Distribution

In line with most companies in Germany
Percentile
38th
Based on 1 747 companies
38th percentile
15.9
Low
0.3 — 12.8
Typical Range
12.8 — 33.7
High
33.7 —
Distribution Statistics
Germany
Min 0.3
30th Percentile 12.8
Median 22
70th Percentile 33.7
Max 8 508.8

Merck KGaA
Glance View

In the heart of Darmstadt, Germany, Merck KGaA stands as a testament to innovation and resilience, tracing its roots back to 1668. A bastion of scientific advancement and a pioneer in the world of chemistry and pharmaceuticals, Merck has evolved through centuries of discovery and transformation. Originally a humble pharmacy, Merck has grown into a global powerhouse with a unique structure, being one of the oldest pharmaceutical and chemical companies in the world still owned by the founding family. Though its path has been influenced by numerous historical events, Merck has adeptly navigated the shifting sands of time, transforming itself into a multifaceted conglomerate that thrives on its dual strategy—life sciences and performance materials. In the modern age, Merck KGaA operates through three well-defined sectors: Healthcare, Life Science, and Electronics. Its Healthcare division plays a formidable role, developing innovative drugs, with a focus on oncology, neurology, and immunology, providing cutting-edge treatments that improve patient lives globally. Meanwhile, the Life Science arm caters to researchers and scientists, offering an extensive portfolio of lab materials, high-tech tools, and equipment essential for groundbreaking research across various industries. The Electronics division, dedicated to performance materials, supplies high-quality substances crucial for the electronics and automotive industries, including liquid crystals and highly sophisticated semiconductor solutions. Through these divisions, Merck KGaA not only generates substantial revenue but also drives progress by supplying critical products that are indispensable to the modern technological landscape.

MKGAF Intrinsic Value
164.97 USD
Undervaluation 19%
Intrinsic Value
Price $132.81
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett